Lucid Diligence Brief: Samsung and GRAIL LOI, Galleri MCED rollout in Asia
Lucid Diligence Brief: Samsung and GRAIL LOI, Galleri MCED rollout in Asia…
Lucid Diligence Brief: EVOQ x Sanofi collaboration
Lucid Diligence Brief: EVOQ x Sanofi collaboration Professional audiences only.…
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040 Professional…
Lucid Diligence Brief: Kailera Therapeutics $600m Series B
Lucid Diligence Brief: Kailera Therapeutics $600m Series B Professional…
Lucid Diligence Brief: Excellergy ECRIs, $70M investment
Lucid Diligence Brief: Excellergy ECRIs, $70M investment Professional audiences…
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close Professional…
Lucid Diligence Brief: Bristol Myers Squibb's acquisition of Orbital Therapeutics
Lucid Diligence Brief: Bristol Myers Squibb's acquisition of Orbital…
How we worked with a multinational Pharma company toward successful market entry in select EU and Latin America countries.
The challenge: Entering a new market. The fine line between "go" and "no-go". A…
How a leading global player in the respiratory space worked towards speedier access to Russia and China
The Challenge: Leading multinational Pharma company wants to dive deep into key…
What a Linkedin poll revealed about the Gene Therapy challenges.
With over 2 million groups where professionals from various industries network,…
